{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-021105","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.281628+00:00","generated_at":"2026-05-14T23:51:59.813706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm","bullets":["Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.","GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.","Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.","FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.","Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021105","json":"https://secwatch.observer/filing/0001493152-26-021105.json","markdown":"https://secwatch.observer/filing/0001493152-26-021105.md","text":"https://secwatch.observer/filing/0001493152-26-021105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/0001493152-26-021105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:51:59.813706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfb58a395f52349df9beefa109c7b23fc4d1f63b","claim":"InspireMD, Inc. reported first quarter ended March 31, 2026 results: revenue $3.4 million, net income $13.7 million, EPS $0.16 per basic and diluted share.","evidence_excerpt":"expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/0001493152-26-021105-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"$13.7 million"},{"label":"EPS","value":"$0.16 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}